<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412372</url>
  </required_header>
  <id_info>
    <org_study_id>39402</org_study_id>
    <nct_id>NCT01412372</nct_id>
  </id_info>
  <brief_title>The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study</brief_title>
  <acronym>Mesalamine</acronym>
  <official_title>The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire Human Genetic Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of long acting mesalamine (Lialda) in&#xD;
      patients with Post-Infective Irritable Bowel Syndrome (PI-IBS). The investigators will&#xD;
      evaluate gastrointestinal symptoms, IBS specific quality of life (IBS-QOL), and plasma&#xD;
      cytokines before and after treatment with Lialda.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test long acting mesalamine in the management of PI-IBS. It has the potential&#xD;
      to improve QOL and perhaps gastrointestinal symptoms, in patients with PI-IBS. The results of&#xD;
      this study, if positive, will provide preliminary data for a large scale clinical trial.&#xD;
&#xD;
      This study will also provide information about plasma cytokines in patients with PI-IBS and&#xD;
      whether improvement in symptoms correlates with improvement in plasma cytokines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 22, 2019</completion_date>
  <primary_completion_date type="Actual">April 22, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>BSS score measured from sum of BSS items of abdominal pain severity, bloating severity, diarrhea severity, constipation severity, and how satisfied are you with bowel habits, and measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Average Overall IBS Specific Quality of Life Score After an 8 Week Treatment Period.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>As measured by the IBS specific Quality of Life questionnaire which consists of 34 items scored on a scale of 0% to 100%, 0 being not at all and 100 being extremely.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Bowel Frequency After 8-Week Treatment Period</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measured by the participant reported average number of daily bowel movements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Bowel Consistency Score After an 8 Week Treatment Period.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measured using the Bristol Stool form scale 1-7, with 1 being the most formed and 7 the least formed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Abdominal Pain Score After an 8 Week Treatment Period</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Bloating Score After an 8 Week Treatment Period.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include those who are randomized to the placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is for subjects randomized to the study drug, Mesalamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine</intervention_name>
    <description>2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
    <arm_group_label>Mesalamine</arm_group_label>
    <other_name>Lialda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is an inactive pill</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Men and women age 18-75 years&#xD;
&#xD;
          2. Rome III criteria for IBS&#xD;
&#xD;
          3. Symptom onset after apparent acute gastroenteritis&#xD;
&#xD;
          4. Symptoms of 6 months or greater duration&#xD;
&#xD;
          5. Normal gross appearance of the colonic mucosa other than erythema&#xD;
&#xD;
          6. Negative markers for celiac disease and inflammatory bowel disease&#xD;
&#xD;
          7. Normal thyroid function and serum calcium&#xD;
&#xD;
          8. Stable medication regimens for other medical conditions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 or &gt;75 years&#xD;
&#xD;
          2. Previous diagnosis of or history compatible with IBS&#xD;
&#xD;
          3. Constipation-predominant IBS.&#xD;
&#xD;
          4. Clinically significant chronic cardiac, pulmonary, hepatic, renal dysfunction or HIV&#xD;
&#xD;
          5. History of/or presence of malignancy&#xD;
&#xD;
          6. Current evidence of any gastrointestinal disorder such as celiac disease, inflammatory&#xD;
             bowel disease, chronic pancreatitis, scleroderma, HIV, small bowel or colonic&#xD;
             resection, paraplegia or quadriplegia. .&#xD;
&#xD;
          7. Current evidence of drug or alcohol abuse as judged by the investigator&#xD;
&#xD;
          8. Allergy to mesalamine or aspirin&#xD;
&#xD;
          9. Investigator perception of patient's inability to comply with the study protocol&#xD;
&#xD;
         10. Unstable psychiatric disease&#xD;
&#xD;
         11. Recent change in gastrointestinal medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashok Tuteja</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <results_first_submitted>September 27, 2020</results_first_submitted>
  <results_first_submitted_qc>December 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Ashok K. Tuteja</investigator_full_name>
    <investigator_title>Associate professor of medicine</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Mesalamine</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>abdominal pain</keyword>
  <keyword>hypersensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01412372/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
        </group>
        <group group_id="P2">
          <title>Mesalamine</title>
          <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
        </group>
        <group group_id="B2">
          <title>Mesalamine</title>
          <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="13"/>
                    <measurement group_id="B2" value="40" spread="12"/>
                    <measurement group_id="B3" value="43" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period</title>
        <description>BSS score measured from sum of BSS items of abdominal pain severity, bloating severity, diarrhea severity, constipation severity, and how satisfied are you with bowel habits, and measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in overall BSS, only 25 placebo participants and 28 mesalamine participants provided data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
          </group>
          <group group_id="O2">
            <title>Mesalamine</title>
            <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period</title>
          <description>BSS score measured from sum of BSS items of abdominal pain severity, bloating severity, diarrhea severity, constipation severity, and how satisfied are you with bowel habits, and measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
          <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in overall BSS, only 25 placebo participants and 28 mesalamine participants provided data for analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="3"/>
                    <measurement group_id="O2" value="-13" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Overall IBS Specific Quality of Life Score After an 8 Week Treatment Period.</title>
        <description>As measured by the IBS specific Quality of Life questionnaire which consists of 34 items scored on a scale of 0% to 100%, 0 being not at all and 100 being extremely.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in average overall IBS specific Quality of Life, only 25 placebo participants and 28 mesalamine participants provided data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
          </group>
          <group group_id="O2">
            <title>Mesalamine</title>
            <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Overall IBS Specific Quality of Life Score After an 8 Week Treatment Period.</title>
          <description>As measured by the IBS specific Quality of Life questionnaire which consists of 34 items scored on a scale of 0% to 100%, 0 being not at all and 100 being extremely.</description>
          <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in average overall IBS specific Quality of Life, only 25 placebo participants and 28 mesalamine participants provided data for analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="4"/>
                    <measurement group_id="O2" value="8" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Bowel Frequency After 8-Week Treatment Period</title>
        <description>Measured by the participant reported average number of daily bowel movements.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
          </group>
          <group group_id="O2">
            <title>Mesalamine</title>
            <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Bowel Frequency After 8-Week Treatment Period</title>
          <description>Measured by the participant reported average number of daily bowel movements.</description>
          <units>Bowel movements per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.5"/>
                    <measurement group_id="O2" value="-0.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Bowel Consistency Score After an 8 Week Treatment Period.</title>
        <description>Measured using the Bristol Stool form scale 1-7, with 1 being the most formed and 7 the least formed.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in average bowel consistency, only 26 placebo participants and 26 mesalamine participants provided data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
          </group>
          <group group_id="O2">
            <title>Mesalamine</title>
            <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Bowel Consistency Score After an 8 Week Treatment Period.</title>
          <description>Measured using the Bristol Stool form scale 1-7, with 1 being the most formed and 7 the least formed.</description>
          <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in average bowel consistency, only 26 placebo participants and 26 mesalamine participants provided data for analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.2"/>
                    <measurement group_id="O2" value="-0.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Abdominal Pain Score After an 8 Week Treatment Period</title>
        <description>Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
          </group>
          <group group_id="O2">
            <title>Mesalamine</title>
            <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Abdominal Pain Score After an 8 Week Treatment Period</title>
          <description>Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="6"/>
                    <measurement group_id="O2" value="-9" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Bloating Score After an 8 Week Treatment Period.</title>
        <description>Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in average bloating, only 25 placebo participants and 28 mesalamine participants provided data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
          </group>
          <group group_id="O2">
            <title>Mesalamine</title>
            <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Bloating Score After an 8 Week Treatment Period.</title>
          <description>Measured on a scale of 0% to 100%, 0 being not severe and 100 being very severe.</description>
          <population>Not all study participants provided complete outcome results at baseline and 8 weeks. For change in average bloating, only 25 placebo participants and 28 mesalamine participants provided data for analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="4"/>
                    <measurement group_id="O2" value="-8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>This arm will include those who are randomized to the placebo&#xD;
Placebo: This is an inactive pill</description>
        </group>
        <group group_id="E2">
          <title>Mesalamine</title>
          <description>This arm is for subjects randomized to the study drug, Mesalamine&#xD;
Mesalamine: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion Sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Increased bowel movement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>light headed/dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sharp pain</sub_title>
                <description>Under left rib cage</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Function Tests</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ashok Tuteja</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-581-5679</phone>
      <email>Ashok.Tuteja@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

